National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010)
made under subsection 85AB(1) of the
National Health Act 1953
Compilation No. 110
Compilation date: 1 March 2021
Includes amendments up to: PB 19 of 2021
Registered: 1 March 2021
About this compilation
This compilation
This is a compilation of the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010) that shows the text of the law as amended and in force on 1 March 2021 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
1 Name of Determination
4 Definition
5 Drugs on F1
6 Drugs on F2
Schedule 1—Drugs on F1
Schedule 2—Drugs on F2
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
1 Name of Determination
(1) This Determination is the National Health (Listed drugs on F1 or F2) Determination 2010.
(2) This Determination may also be cited as PB 93 of 2010.
4 Definition
In this Determination:
Act means the National Health Act 1953.
5 Drugs on F1
For subsection 85AB(1) of the Act, the drugs mentioned in Schedule 1 are on F1.
6 Drugs on F2
For subsection 85AB(1) of the Act, the drugs mentioned in Schedule 2 are on F2.
Schedule 1—Drugs on F1
(section 5)
Abacavir |
Abemaciclib |
Abiraterone |
Acalabrutinib |
Acetazolamide |
Aclidinium |
Adalimumab |
Adapalene with benzoyl peroxide |
Afatinib |
Aflibercept |
Albendazole |
Alectinib |
Alemtuzumab |
Alogliptin |
Amantadine |
Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids |
Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine |
Amino acid formula with carbohydrate without phenylalanine |
Amino acid formula with fat, carbohydrate, vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine and supplemented with docosahexaenoic acid |
Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without methionine and supplemented with docosahexanoic acid |
Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine |
Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine |
Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides |
Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine and supplemented with docosahexanoic acid |
Amino acid formula with fat, carbohydrate without methionine |
Amino acid formula with fat, carbohydrate without phenylalanine |
Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine |
Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine |
Amino acid formula with vitamins and minerals and long chain polyunsaturated fatty acids without phenylalanine |
Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid |
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid |
Amino acid formula with vitamins and minerals without lysine and low in tryptophan |
Amino acid formula with vitamins and minerals without methionine |
Amino acid formula with vitamins and minerals without methionine, threonine and valine, and low in isoleucine |
Amino acid formula with vitamins and minerals without phenylalanine |
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine |
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine |
Amino acid formula without phenylalanine |
Amino acid formula without valine, leucine and isoleucine |
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids |
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides |
Amino acids—synthetic, formula |
Amphotericin B |
Amylopectin, modified long chain |
Anakinra |
Apixaban |
Apraclonidine |
Apremilast |
Aprepitant |
Arachidonic acid and docosahexaenoic acid with carbohydrate |
Arginine with carbohydrate |
Armodafinil |
Artemether with lumefantrine |
Asenapine |
Atezolizumab |
Atovaquone |
Atropine |
Auranofin |
Avelumab |
Axitinib |
Balsalazide |
Baricitinib |
Beclometasone |
Bendamustine |
Benralizumab |
Benzathine benzylpenicillin |
Benzatropine |
Benzydamine |
Benzylpenicillin |
Betaine |
Bethanechol |
Bevacizumab |
Binimetinib |
Blinatumomab |
Bortezomib |
Botulinum toxin type A purified neurotoxin complex |
Brentuximab vedotin |
Brexpiprazole |
Brigatinib |
Brivaracetam |
Budesonide |
Busulfan |
Cabazitaxel |
Cabozantinib |
Calcitonin salmon |
Calcium |
Carbimazole |
Carbohydrate, fat, vitamins, minerals and trace elements |
Carbohydrate, fat, vitamins, minerals and trace elements and supplemented with arachidonic acid and docosahexaenoic acid |
Carbomer 974 |
Carfilzomib |
Carmellose |
Carmustine |
Ceritinib |
Cetrorelix |
Cetuximab |
Chlorambucil |
Chloramphenicol |
Chlorpromazine |
Chlortalidone |
Choriogonadotropin alfa |
Ciclesonide |
Cinacalcet |
Citrulline |
Citrulline with carbohydrate |
Cladribine |
Clobetasol |
Clostridium Botulinum Type A Toxin‑haemagglutinin Complex |
Cobimetinib |
Codeine |
Colestyramine |
Corifollitropin alfa |
Cortisone |
Crizotinib |
Cyclophosphamide |
Cytarabine |
Dabigatran etexilate |
Dabrafenib |
Dalteparin |
Dantrolene |
Dapagliflozin |
Dapsone |
Daratumumab |
Darbepoetin alfa |
Darunavir |
Dasatinib |
Deferasirox |
Deferiprone |
Degarelix |
Denosumab |
Desmopressin |
Dexamfetamine |
Dimethyl fumarate |
Diptheria and tetanus vaccine, adsorbed, diluted for adult use |
Disopyramide |
Dolutegravir |
Docosahexaenoic acid with carbohydrate |
Domperidone |
Dornase alfa |
Doxepin |
Dulaglutide |
Dupilumab |
Durvalumab |
Eculizumab |
Efavirenz |
Eletriptan |
Eltrombopag |
Empagliflozin |
Emtricitabine with tenofovir alafenamide |
Encorafenib |
Enfuvirtide |
Entacapone |
Entrectinib |
Enzalutamide |
Epoetin Alfa |
Epoetin Beta |
Epoetin Lambda |
Eptifibatide |
Eribulin |
Erlotinib |
Ertugliflozin |
Essential amino acids formula |
Essential amino acids formula with minerals and vitamin C |
Essential amino acids formula with vitamins and minerals |
Estriol |
Etacrynic acid |
Ethosuximide |
Etonogestrel |
Etravirine |
Evolocumab |
Exenatide |
Febuxostat |
Ferric carboxymaltose |
Ferric derisomaltose |
Ferrous fumarate |
Ferrous Sulfate |
Fingolimod |
Fludrocortisone |
Fluorometholone |
Flupentixol decanoate |
Fluticasone furoate |
Folic acid |
Follitropin Beta |
Follitropin delta |
Fondaparinux |
Formoterol |
Fosamprenavir |
Fosaprepitant |
Fotemustine |
Framycetin |
Fusidic acid |
Ganirelix |
Glatiramer |
Glecaprevir with pibrentasvir |
Glucagon |
Glucose and ketone indicator urine |
Glucose indicator—urine |
Glycine with carbohydrate |
Glycomacropeptide and essential amino acid formula with vitamins, minerals, and low in tyrosine and phenylalanine |
Glycomacropeptide and essential amino acids with vitamins and minerals |
Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine |
Glycopyrronium |
Golimumab |
Goserelin |
Grazoprevir with elbasvir |
Griseofulvin |
Guanfacine |
Guselkumab |
Haloperidol |
Haloperidol decanoate |
Heparin |
High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate |
Human Menopausal Gonadotrophin |
Hyaluronic acid |
Hydralazine |
Hydrochlorothiazide |
Hydroxyethyl starch 130/0.4 |
Ibandronic acid |
Ibrutinib |
Idelalisib |
Ifosfamide |
Iloprost |
IncobotulinumtoxinA |
Indacaterol |
Inotuzumab ozogamicin |
Insect allergen extract—honey bee venom |
Insect allergen extract—paper wasp venom |
Insect allergen extract—yellow jacket venom |
Insulin aspart |
Insulin detemir |
Insulin glulisine |
Insulin isophane |
Insulin lispro |
Insulin neutral |
Interferon alfa‑2a |
Interferon beta‑1a |
Interferon gamma‑1b |
Ipilimumab |
Iron sucrose |
Isoleucine with carbohydrate |
Isoniazid |
Ivacaftor |
Ivermectin |
Ixekizumab |
Ketoconazole |
Lacosamide |
Lanreotide |
Lanthanum |
Lapatinib |
Ledipasvir with sofosbuvir |
Lenalidomide |
Lenograstim |
Lenvatinib |
Leuprorelin |
Levodopa with benserazide |
Levonorgestrel |
Lidocaine |
Linagliptin |
Liothyronine |
Lipegfilgrastim |
Lisdexamfetamine |
Lithium |
Lorlatinib |
Lutropin alfa |
Macitentan |
Mannitol |
Maraviroc |
Magnesium |
Mefenamic acid |
Melphalan |
Mepolizumab |
Mesalazine |
Mesna |
Methoxsalen |
Methoxy polyethylene glycol‑epoetin beta |
Methoxyflurane |
Methylnaltrexone |
Miconazole |
Midazolam |
Midostaurin |
Mifepristone and misoprostol |
Milk powder—synthetic |
Milk protein and fat formula with vitamins and minerals—carbohydrate free |
Minoxidil |
Mupirocin |
Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain |
Nadroparin |
Nafarelin |
Naratriptan |
Natalizumab |
Nedocromil |
Nicotine |
Nintedanib |
Nilotinib |
Nilutamide |
Nivolumab |
Nusinersen |
Nystatin |
Obinutuzumab |
Ocrelizumab |
Ocriplasmin |
Ofloxacin |
Olaparib |
Olsalazine |
Osimertinib |
Oxcarbazepine |
Oxprenolol |
Ozanimod |
Paclitaxel, nanoparticle albumin‑bound |
Palbociclib |
Paliperidone |
Palonosetron |
Pancreatic extract |
Pancrelipase |
Panitumumab |
Pasireotide |
Pazopanib |
Peginterferon alfa‑2a |
Peginterferon Beta‑1a |
Pegvisomant |
Pembrolizumab |
Penicillamine |
Perampanel |
Perfluorohexyloctane |
Perhexiline |
Periciazine |
Permethrin |
Pertuzumab |
Phenelzine |
Phenobarbital |
Phenoxybenzamine |
Phenylalanine with carbohydrate |
Phenytoin |
Phytomenadione |
Pimecrolimus |
Pirfenidone |
Pizotifen |
Plerixafor |
Poly‑L‑Lactic acid |
Polyethylene Glycol 400 with Propylene Glycol |
Pomalidomide |
Ponatinib |
Pralatrexate |
Praziquantel |
Primidone |
Probenecid |
Procaine benzylpenicillin |
Progesterone |
Promethazine |
Propantheline |
Propylthiouracil |
Protein formula with amino acids, carbohydrates, vitamins and minerals without phenylalanine, and supplemented with docosahexaenoic acid |
Protein formula with carbohydrate, fat, vitamins and minerals |
Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A |
Protein hydrolysate formula with medium chain triglycerides |
Pyrantel |
Pyridostigmine |
Quinagolide |
Raltegravir |
Raltitrexed |
Ranibizumab |
Reboxetine |
Reteplase |
Ribavirin |
Ribociclib |
Rifabutin |
Rifampicin |
Rifaximin |
Rilpivirine |
Riociguat |
Risankizumab |
Ritonavir |
Rivaroxaban |
Romiplostim |
Rotigotine |
Ruxolitinib |
Safinamide |
Salmeterol |
Sapropterin |
Saquinavir |
Saxagliptin |
Secukinumab |
Selexipag |
Semaglutide |
Silver sulfadiazine |
Siponimod |
Sirolimus |
Sitagliptin |
Sodium acid phosphate |
Sodium bicarbonate |
Sodium phenylbutyrate |
Sofosbuvir with velpatasvir |
Sonidegib |
Sorafenib |
Soy Lecithin |
Soy protein and fat formula with vitamins and minerals—carbohydrate free |
Sterculia with frangula bark |
Stiripentol |
Sucroferric oxyhydroxide |
Sulthiame |
Sunitinib |
Tafluprost |
Tapentadol |
Teduglutide |
Tenecteplase |
Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat |
Terbutaline |
Teriparatide |
Testosterone |
Tetrabenazine |
Tetracosactide |
Thalidomide |
Theophylline |
Thiamine |
Thyrotropin alfa |
Tiagabine |
Ticagrelor |
Tildrakizumab |
Tioguanine |
Tipranavir |
Tofacitinib |
Tolvaptan |
Toremifene |
Trametinib |
Tranylcypromine |
Trastuzumab emtansine |
Travoprost |
Trifluridine with tipiracil |
Triglycerides, long chain with glucose polymer |
Triglycerides, medium chain |
Triglycerides, medium chain and long chain with glucose polymer |
Triglycerides—medium chain, formula |
Trihexyphenidyl |
Triptorelin |
Tyrosine with carbohydrate |
Umeclidinium |
Upadacitinib |
Ustekinumab |
Valine with carbohydrate |
Varenicline |
Vedolizumab |
Vemurafenib |
Venetoclax |
Vigabatrin |
Vildagliptin |
Vinblastine |
Vismodegib |
Vitamins, minerals and trace elements formula |
Vitamins, minerals and trace elements with carbohydrate |
Vorinostat |
Warfarin |
Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose |
Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose |
Zidovudine |
Zuclopenthixol Decanoate |
Schedule 2—Drugs on F2
(section 6)
Abacavir with Lamivudine | |
Abatacept | |
Acamprosate | |
Acarbose | |
Aciclovir | |
Acitretin | |
Adefovir | |
Adrenaline (epinephrine) | |
Alendronic acid | |
Alendronic acid with colecalciferol | |
Alendronic acid with colecalciferol and calcium | |
Allopurinol | |
Alprazolam | |
Ambrisentan | |
Amiodarone | |
Amisulpride | |
Amitriptyline | |
Amlodipine | |
Amlodipine with Atorvastatin | |
Amlodipine with valsartan | |
Amlodipine with valsartan and hydrochlorothiazide | |
Amoxicillin | |
Amoxicillin with clavulanic acid | |
Ampicillin | |
Anastrozole | |
Apomorphine | |
Aripiprazole | |
Arsenic | |
Aspirin | |
Atazanavir | |
Atenolol | |
Atomoxetine | |
Atorvastatin | |
Azacitidine | |
Azathioprine | |
Azithromycin | |
Baclofen | |
Betamethasone | |
Betaxolol | |
Bicalutamide | |
Bimatoprost | |
Bisacodyl | |
Bisoprolol | |
Bivalirudin | |
Bleomycin | |
Bosentan | |
Brimonidine | |
Brinzolamide | |
Bromocriptine | |
Budesonide with formoterol | |
Buprenorphine | |
Bupropion | |
Cabergoline | |
Calcipotriol with betamethasone | |
Calcitriol | |
Candesartan | |
Candesartan with Hydrochlorothiazide | |
Capecitabine | |
Captopril | |
Carbamazepine | |
Carbomer | |
Carboplatin | |
Carvedilol | |
Cefaclor | |
Cefalexin | |
Cefalotin | |
Cefazolin | |
Cefepime | |
Cefotaxime | |
Ceftriaxone | |
Cefuroxime | |
Celecoxib | |
Certolizumab pegol | |
Chorionic gonadotrophin | |
Ciclosporin | |
Cimetidine | |
Ciprofloxacin | |
Cisplatin | |
Citalopram | |
Clarithromycin | |
Clindamycin | |
Clomifene | |
Clomipramine | |
Clonazepam | |
Clonidine | |
Clopidogrel | |
Clopidogrel with aspirin | |
Clozapine | |
Codeine with paracetamol | |
Colchicine | |
Cromoglycic acid | |
Cyproterone | |
Desferrioxamine | |
Desvenlafaxine | |
Dexamethasone | |
Dexamethasone with framycetin and gramicidin | |
Diazepam | |
Diclofenac | |
Dicloxacillin | |
Digoxin | |
Diltiazem | |
Diphenoxylate with atropine | |
Dipyridamole with Aspirin | |
Docetaxel | |
Donepezil | |
Dorzolamide | |
Dorzolamide with timolol | |
Dosulepin | |
Doxorubicin | |
Doxorubicin – Pegylated Liposomal | |
Doxycycline | |
Duloxetine | |
Dutasteride | |
Dutasteride with tamsulosin | |
Electrolyte Replacement, Oral | |
Enalapril | |
Enalapril with hydrochlorothiazide | |
Enoxaparin | |
Entecavir | |
Epirubicin | |
Eplerenone | |
Epoprostenol | |
Eprosartan | |
Erythromycin | |
Escitalopram | |
Esomeprazole | |
Esomeprazole and clarithromycin and amoxicillin | |
Estradiol | |
Etanercept | |
Etoposide | |
Everolimus | |
Exemestane | |
Ezetimibe | |
Ezetimibe and rosuvastatin | |
Ezetimibe with atorvastatin | |
Ezetimibe with simvastatin | |
Famciclovir | |
Famotidine | |
Felodipine | |
Fenofibrate | |
Fentanyl | |
Filgrastim | |
Flecainide | |
Flucloxacillin | |
Fluconazole | |
Fludarabine | |
Fluorouracil | |
Fluoxetine | |
Flutamide | |
Fluticasone propionate | |
Fluticasone propionate with salmeterol | |
Fluvastatin | |
Fluvoxamine | |
Folinic acid | |
Follitropin Alfa | |
Fosinopril | |
Fosinopril with hydrochlorothiazide | |
Furosemide | |
Gabapentin | |
Galantamine | |
Ganciclovir | |
Gefitinib | |
Gemcitabine | |
Gemfibrozil | |
Gentamicin | |
Glibenclamide | |
Gliclazide | |
Glimepiride | |
Glipizide | |
Glyceryl trinitrate | |
Granisetron | |
Hydrochlorothiazide with amiloride | |
Hydrocortisone | |
Hydromorphone | |
Hydroxocobalamin | |
Hydroxycarbamide | |
Hydroxychloroquine | |
Hyoscine | |
Hypromellose | |
Hypromellose with carbomer 980 | |
Hypromellose with dextran | |
Ibuprofen | |
Icatibant | |
Idarubicin | |
Imatinib | |
Imipramine | |
Imiquimod | |
Indapamide | |
Indometacin | |
Infliximab | |
Insulin glargine | |
Interferon beta‑1b | |
Ipratropium | |
Irbesartan | |
Irbesartan with Hydrochlorothiazide | |
Irinotecan | |
Iron polymaltose complex | |
Isosorbide dinitrate | |
Isosorbide Mononitrate | |
Isotretinoin | |
Itraconazole | |
Ivabradine | |
Ketoprofen | |
Labetalol | |
Lamivudine | |
Lamivudine with Zidovudine | |
Lamotrigine | |
Lansoprazole | |
Latanoprost | |
Latanoprost with timolol | |
Leflunomide | |
Lercanidipine | |
Letrozole | |
Levetiracetam | |
Levodopa with carbidopa | |
Levodopa with carbidopa and entacapone | |
Levonorgestrel with ethinylestradiol | |
Levothyroxine | |
Lincomycin | |
Lisinopril | |
Loperamide | |
Losartan | |
Lurasidone | |
Macrogol 3350 | |
Medroxyprogesterone | |
Meloxicam | |
Memantine | |
Mercaptopurine | |
Metformin | |
Methadone | |
Methenamine | |
Methotrexate | |
Methyldopa | |
Methylphenidate | |
Methylprednisolone | |
Metoclopramide | |
Metoprolol | |
Metoprolol succinate | |
Metronidazole | |
Mianserin | |
Minocycline | |
Mirtazapine | |
Mitozantrone | |
Moclobemide | |
Modafinil | |
Mometasone | |
Montelukast | |
Morphine | |
Moxonidine | |
Mycophenolic acid | |
Naloxone | |
Naltrexone | |
Naproxen | |
Nebivolol | |
Nevirapine | |
Nicorandil | |
Nifedipine | |
Nitrazepam | |
Nitrofurantoin | |
Nizatidine | |
Norethisterone | |
Norethisterone with ethinylestradiol | |
Norfloxacin | |
Nortriptyline | |
Octreotide | |
Olanzapine | |
Olmesartan | |
Olmesartan with amlodipine | |
Olmesartan with amlodipine and hydrochlorothiazide | |
Olmesartan with hydrochlorothiazide | |
Omalizumab | |
Omeprazole | |
Ondansetron | |
Oxaliplatin | |
Oxazepam | |
Oxybutynin | |
Oxycodone | |
Paclitaxel | |
Pamidronic acid | |
Pantoprazole | |
Paracetamol | |
Paraffin | |
Paraffin with retinol palmitate | |
Paroxetine | |
Pegfilgrastim | |
Pemetrexed | |
Perindopril | |
Perindopril with amlodipine | |
Perindopril with indapamide | |
Phenoxymethylpenicillin | |
Pilocarpine | |
Pindolol | |
Pioglitazone | |
Piroxicam | |
Polyvinyl alcohol | |
Posaconazole | |
Potassium chloride | |
Potassium chloride with potassium bicarbonate | |
Pramipexole | |
Pravastatin | |
Prazosin | |
Prednisolone | |
Prednisone | |
Pregabalin | |
Prochlorperazine | |
Propranolol | |
Quetiapine | |
Quinapril | |
Quinine | |
Rabeprazole | |
Raloxifene | |
Ramipril | |
Ranitidine | |
Rasagiline | |
Riluzole | |
Risedronic acid | |
Risedronic acid and Calcium | |
Risperidone | |
Rituximab | |
Rivastigmine | |
Rizatriptan | |
Rosuvastatin | |
Roxithromycin | |
Salbutamol | |
Selegiline | |
Sertraline | |
Sevelamer | |
Sildenafil | |
Simvastatin | |
Somatropin | |
Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | |
Sotalol | |
Spironolactone | |
Sucralfate | |
Sulfasalazine | |
Sumatriptan | |
Tacrolimus | |
Tadalafil | |
Tamoxifen | |
Telmisartan | |
Telmisartan with amlodipine | |
Telmisartan with Hydrochlorothiazide | |
Temazepam | |
Temozolomide | |
Tenofovir | |
Tenofovir with emtricitabine | |
Tenofovir with emtricitabine and efavirenz | |
Terbinafine | |
Teriflunomide | |
Timolol | |
Tiotropium | |
Tirofiban | |
Tobramycin | |
Tocilizumab | |
Topiramate | |
Topotecan | |
Tramadol | |
Trandolapril | |
Tranexamic acid | |
Trastuzumab | |
Triamcinolone | |
Triamcinolone with neomycin, gramicidin and nystatin | |
Trimethoprim | |
Trimethoprim with sulfamethoxazole | |
Tropisetron | |
Ursodeoxycholic acid | |
Valaciclovir | |
Valganciclovir | |
Valproic acid | |
Valsartan | |
Valsartan with hydrochlorothiazide | |
Vancomycin | |
Venlafaxine | |
Verapamil | |
Vincristine | |
Vinorelbine | |
Voriconazole | |
Ziprasidone | |
Zoledronic acid | |
Zolmitriptan | |
Zonisamide | |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
ad = added or inserted | o = order(s) |
am = amended | Ord = Ordinance |
amdt = amendment | orig = original |
c = clause(s) | par = paragraph(s)/subparagraph(s) |
C[x] = Compilation No. x | /sub‑subparagraph(s) |
Ch = Chapter(s) | pres = present |
def = definition(s) | prev = previous |
Dict = Dictionary | (prev…) = previously |
disallowed = disallowed by Parliament | Pt = Part(s) |
Div = Division(s) | r = regulation(s)/rule(s) |
ed = editorial change | reloc = relocated |
exp = expires/expired or ceases/ceased to have | renum = renumbered |
effect | rep = repealed |
F = Federal Register of Legislation | rs = repealed and substituted |
gaz = gazette | s = section(s)/subsection(s) |
LA = Legislation Act 2003 | Sch = Schedule(s) |
LIA = Legislative Instruments Act 2003 | Sdiv = Subdivision(s) |
(md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
effect | SR = Statutory Rules |
(md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
cannot be given effect | SubPt = Subpart(s) |
mod = modified/modification | underlining = whole or part not |
No. = Number(s) | commenced or to be commenced |
Endnote 3—Legislation history
Name | Registration | Commencement | Application, saving and transitional provisions |
PB 93 of 2010 | 8 Oct 2010 (F2010L02642) | 11 Oct 2010 |
|
PB 107 of 2010 | 29 Oct 2010 (F2010L02863) | 1 Nov 2010 | — |
PB 112 of 2010 | 30 Nov 2010 (F2010L03131) | 1 Dec 2010 | — |
PB 9 of 2011 | 31 Jan 2011 (F2011L00167) | 1 Feb 2011 | s 1(1) as am. by PB 19 of 2011 |
as amended by |
|
|
|
PB 19 of 2011 | 31 Jan 2011 (F2011L00172) | 1 Feb 2011 | — |
PB 20 of 2011 | 28 Feb 2011 (F2011L00323) | 1 Mar 2011 | — |
PB 27 of 2011 | 31 Mar 2011 (F2011L00544) | 1 Apr 2011 | — |
PB 33 of 2011 | 20 Apr 2011 (F2011L00623) | 1 May 2011 | — |
PB 40 of 2011 | 25 May 2011 (F2011L00859) | 1 June 2011 | — |
PB 44 of 2011 | 17 June 2011 (F2011L01065) | 1 July 2011 | — |
PB 51 of 2011 | 29 July 2011 (F2011L01557) | 1 Aug 2011 | — |
PB 60 of 2011 | 30 Aug 2011 (F2011L01772) | 1 Sept 2011 | — |
PB 71 of 2011 | 29 Sept 2011 (F2011L01994) | 1 Oct 2011 | — |
PB 77 of 2011 | 26 Oct 2011 (F2011L02133) | 1 Nov 2011 | — |
PB 90 of 2011 | 29 Nov 2011 (F2011L02495) | 1 Dec 2011 | — |
PB 98 of 2011 | 15 Dec 2011 (F2011L02699) | 1 Jan 2012 | — |
PB 10 of 2012 | 21 Feb 2012 (F2012L00346) | 1 Mar 2012 | — |
PB 17 of 2012 | 30 Mar 2012 (F2012L00727) | 1 Apr 2012 | — |
PB 30 of 2012 | 24 May 2012 (F2012L01074) | 1 June 2012 | — |
PB 41 of 2012 | 15 June 2012 (F2012L01208) | 1 July 2012 | — |
PB 53 of 2012 | 30 July 2012 (F2012L01621) | 1 Aug 2012 | — |
PB 67 of 2012 | 21 Aug 2012 (F2012L01716) | 1 Sept 2012 | — |
PB 81 of 2012 | 26 Sept 2012 (F2012L01938) | 1 Oct 2012 | — |
PB 99 of 2012 | 29 Nov 2012 (F2012L02282) | 1 Dec 2012 | — |
PB 12 of 2013 | 27 Feb 2013 (F2013L00329) | 1 Mar 2013 | — |
PB 19 of 2013 | 28 Mar 2013 (F2013L00575) | 1 Apr 2013 | — |
PB 46 of 2013 | 29 July 2013 (F2013L01454) | 1 Aug 2013 | — |
PB 58 of 2013 | 16 Aug 2013 (F2013L01585) | 1 Sept 2013 | — |
PB 68 of 2013 | 18 Sept 2013 (F2013L01707) | 1 Oct 2013 | — |
PB 73 of 2013 | 16 Oct 2013 (F2013L01800) | 1 Nov 2013 | — |
PB 76 of 2013 | 29 Nov 2013 (F2013L02008) | 1 Dec 2013 | — |
PB 15 of 2014 | 21 Feb 2014 (F2014L00171) | 1 Mar 2014 | — |
PB 22 of 2014 | 27 Mar 2014 (F2014L00358) | 1 Apr 2014 | — |
PB 32 of 2014 | 15 Apr 2014 (F2014L00413) | 1 May 2014 | — |
PB 43 of 2014 | 21 May 2014 (F2014L00580) | 1 June 2014 | — |
PB 47 of 2014 | 19 June 2014 (F2014L00762) | 1 July 2014 | — |
PB 54 of 2014 | 30 July 2014 (F2014L01051) | 1 Aug 2014 | — |
PB 66 of 2014 | 7 Aug 2014 (F2014L01075) | 8 Aug 2014 | — |
PB 70 of 2014 | 29 Aug 2014 (F2014L01171) | 1 Sept 2014 | — |
PB 76 of 2014 | 30 Sept 2014 (F2014L01171) | 1 Oct 2014 | — |
PB 85 of 2014 | 30 Oct 2014 (F2014L01440) | 1 Nov 2014 (s 2) | — |
PB 95 of 2014 | 1 Dec 2014 (F2014L01609) | 1 Dec 2014 (s 2) | — |
PB 105 of 2014 | 23 Dec 2014 (F2014L01808) | 1 Jan 2015 (s 2) | — |
PB 6 of 2015 | 29 Jan 2015 (F2015L00082) | 1 Feb 2015 (s 2) | — |
PB 15 of 2015 | 27 Feb 2015 (F2015L00222) | 1 Mar 2015 (s 2) | — |
PB 35 of 2015 | 30 Mar 2015 (F2015L00377) | 1 Apr 2015 (s 2) | — |
PB 52 of 2015 | 29 May 2015 (F2015L00755) | 1 June 2015 (s 2) | — |
PB 61 of 2015 | 1 July 2015 (F2015L01081) | 1 July 2015 (s 2) | — |
PB 75 of 2015 | 31 July 2015 (F2015L01208) | 1 Aug 2015 (s 2) | — |
PB 82 of 2015 | 31 Aug 2015 (F2015L01360) | 1 Sept 2015 (s 2) | — |
PB 98 of 2015 | 1 Oct 2015 (F2015L01599) | 1 Oct 2015 (s 2) | — |
PB 106 of 2015 | 29 Oct 2015 (F2015L01717) | 1 Nov 2015 (s 2) | — |
PB 113 of 2015 | 1 Dec 2015 (F2015L01902) | 1 Dec 2015 (s 2) | — |
PB 123 of 2015 | 24 Dec 2015 (F2015L02136) | 1 Jan 2016 (s 2) | — |
PB 7 of 2016 | 1 Feb 2016 (F2016L00082) | 1 Feb 2016 (s 2) | — |
PB 16 of 2016 | 29 Feb 2016 (F2016L00185) | 1 Mar 2016 (s 2) | — |
PB 26 of 2016 | 1 Apr 2016 (F2016L00468) | 1 Apr 2016 (s 2) | — |
PB 37 of 2016 | 29 Apr 2016 (F2016L00608) | 1 May 2016 (s 2) | — |
PB 48 of 2016 | 31 May 2016 (F2016L00864) | 1 June 2016 (s 2) | — |
PB 57 of 2016 | 23 June 2016 (F2016L01068) | 1 July 2016 (s 2) | — |
PB 70 of 2016 | 28 July 2016 (F2016L01243) | 1 Aug 2016 (s 2) | — |
PB 78 of 2016 | 26 Aug 2016 (F2016L01336) | 1 Sept 2016 (s 2) | — |
PB 88 of 2016 | 29 Sept 2016 (F2016L01546) | 1 Oct 2016 (s 2) | — |
PB 95 of 2016 | 28 Oct 2016 (F2016L01650) | 1 Nov 2016 (s 2) | — |
as amended by |
|
|
|
PB 96 of 2016 | 31 Oct 2016 (F2016L01690) | 11.59 pm 31 Oct 2016 (s 2) | — |
PB 104 of 2016 | 30 Nov 2016 (F2016L01833) | 1 Dec 2016 (s 2) | — |
PB 112 of 2016 | 22 Dec 2016 (F2016L02033) | 1 Jan 2017 (s 2) | — |
PB 9 of 2017 | 27 Jan 2017 (F2017L00076) | 1 Feb 2017 (s 2) | — |
PB 22 of 2017 | 30 Mar 2017 (F2017L00361) | 1 Apr 2017 (s 2) | — |
PB 32 of 2017 | 28 Apr 2017 (F2017L00486) | 1 May 2017 (s 2) | — |
PB 41 of 2017 | 31 May 2017 (F2017L00623) | 1 June 2017 (s 2) | — |
PB 49 of 2017 | 29 June 2017 (F2017L00819) | 1 July 2017 (s 2) | — |
PB 60 of 2017 | 28 July 2017 (F2017L00970) | 1 Aug 2017 (s 2) | — |
PB 68 of 2017 | 30 Aug 2017 (F2017L01110) | 1 Sept 2017 (s 2) | — |
PB 79 of 2017 | 29 Sept 2017 (F2017L01304) | 1 Oct 2017 (s 2) | — |
PB 97 of 2017 | 29 Nov 2017 (F2017L01544) | 1 Dec 2017 (s 2) | — |
PB 106 of 2017 | 18 Dec 2017 (F2017L01630) | 1 Jan 2018 (s 2) | — |
PB 10 of 2018 | 31 Jan 2018 (F2018L00071) | 1 Feb 2018 (s 2) | — |
PB 25 of 2018 | 28 Mar 2018 (F2018L00426) | 1 Apr 2018 (s 2) | — |
PB 34 of 2018 | 30 Apr 2018 (F2018L00538) | 1 May 2018 (s 2) | — |
PB 43 of 2018 | 31 May 2018 (F2018L00693) | 1 June 2018 (s 2) | — |
PB 59 of 2018 | 29 June 2018 (F2018L00946) | 1 July 2018 (s 2) | — |
PB 70 of 2018 | 1 Aug 2018 (F2018L01079) | 1 Aug 2018 (s 2) | — |
PB 81 of 2018 | 30 Aug 2018 (F2018L01222) | 1 Sept 2018 (s 2) | — |
PB 87 of 2018 | 27 Sept 2018 (F2018L01349) | 1 Oct 2018 (s 2) | — |
PB 104 of 2018 | 29 Nov 2018 (F2018L01631) | 1 Dec 2018 (s 2) | — |
PB 114 of 2018 | 20 Dec 2018 (F2018L01809) | 1 Jan 2019 (s 2) | — |
PB 5 of 2019 | 31 Jan 2019 (F2019L00077) | 1 Feb 2019 (s 2) | — |
PB 15 of 2019 | 27 Feb 2019 (F2019L00209) | 1 Mar 2019 (s 2) | — |
PB 24 of 2019 | 28 Mar 2019 (F2019L00449) | 1 Apr 2019 (s 2) | — |
PB 33 of 2019 | 30 Apr 2019 (F2019L00653) | 1 May 2019 (s 2) | — |
PB 41 of 2019 | 30 May 2019 (F2019L00702) | 1 June 2019 (s 2) | — |
PB 53 of 2019 | 28 June 2019 (F2019L00909) | 1 July 2019 (s 2) | — |
PB 63 of 2019 | 30 July 2019 (F2019L01016) | 1 Aug 2019 (s 2) | — |
PB 72 of 2019 | 30 Aug 2019 (F2019L01127) | 1 Sept 2019 (s 2) | — |
PB 81 of 2019 | 30 Sept 2019 (F2019L01298) | 1 Oct 2019 (s 2) | — |
PB 89 of 2019 | 31 Oct 2019 (F2019L01392) | 1 Nov 2019 (s 2) | — |
PB 98 of 2019 | 28 Nov 2019 (F2019L01516) | 1 Dec 2019 (s 2) | — |
PB 111 of 2019 | 23 Dec 2019 (F2019L01698) | 1 Jan 2020 (s 2) | — |
PB 8 of 2020 | 31 Jan 2020 (F2020L00075) | 1 Feb 2020 (s 2) | — |
PB 19 of 2020 | 28 Feb 2020 (F2020L00188) | 1 Mar 2020 (s 2) | — |
PB 26 of 2020 | 31 Mar 2020 (F2020L00357) | 1 Apr 2020 (s 2) | — |
PB 39 of 2020 | 30 Apr 2020 (F2020L00526) | 1 May 2020 (s 2) | — |
PB 48 of 2020 | 29 May 2020 (F2020L00642) | 1 June 2020 (s 2) | — |
PB 61 of 2020 | 30 June 2020 (F2020L00843) | 1 July 2020 (s 2) | — |
PB 73 of 2020 | 31 July 2020 (F2020L00976) | 1 Aug 2020 (s 2) | — |
PB 84 of 2020 | 28 Aug 2020 (F2020L01087) | 1 Sept 2020 (s 2) | — |
PB 95 of 2020 | 30 Sept 2020 (F2020L01251) | 1 Oct 2020 (s 2(1) item 1) | — |
PB 108 of 2020 | 30 Oct 2020 (F2020L01359) | 1 Nov 2020 (s 2(1) item 1) | — |
PB 117 of 2020 | 27 Nov 2020 (F2020L01499) | 1 Dec 2020 (s 2(1) item 1) | — |
PB 131 of 2020 | 23 Dec 2020 (F2020L01700) | 1 Jan 2021 (s 2(1) item 1) | — |
PB 6 of 2021 | 28 Jan 2021 (F2021L00078) | 1 Feb 2021 (s 2(1) item 1) | — |
PB 19 of 2021 | 25 Feb 2021 (F2021L00148) | 1 Mar 2021 (s 2(1) item 1) | — |
Endnote 4—Amendment history
Provision affected | How affected |
s 2..................... | rep LA s 48D |
s 3..................... | rep LA s 48C |
Schedule 1 |
|
Schedule 1................ | am PB 107 and 112 of 2010; PB 9, 20, 27, 33, 40, 44, 51, 60, 77, 90 and 98 of 2011; PB 10, 17, 41, 53, 67, 81 and 99 of 2012; PB 12, 19, 46, 58, 68, 73 and 76 of 2013; PB 15, 22, 32, 43, 47, 54, 66, 70, 76, 85, 95 and 105 of 2014; PB 6, 15, 35, 52, 61, 75, 82, 98, 106, 113 and 123 of 2015; PB 7, 16, 26, 37, 48, 57, 70, 78, 88 (Sch 1 item 2 md), 95 (as am by PB 96 of 2016), 104 and 112 of 2016; PB 9 of 2017; PB 22 of 2017; PB 32 of 2017; PB 41 of 2017; PB 49 of 2017; PB 60 of 2017; PB 68 of 2017; PB 79 of 2017; PB 97 of 2017; PB 106 of 2017; PB 10 of 2018; PB 25 of 2018; PB 34 of 2018; PB 43 of 2018; PB 59 of 2018; PB 70 of 2018; PB 81 of 2018; PB 87 of 2018; PB 104 of 2018; PB 114 of 2018; PB 5 of 2019; PB 15 of 2019; PB 24 of 2019; PB 33 of 2019; PB 41 of 2019; PB 53 of 2019; PB 63 of 2019; PB 72 of 2019; PB 81 of 2019; PB 89 of 2019; PB 98 of 2019; PB 111 of 2019; PB 8 of 2020; PB 19 of 2020; PB 26 of 2020; PB 39 of 2020; PB 48 of 2020; PB 61 of 2020; PB 73 of 2020; PB 84 of 2020; PB 95 of 2020; PB 108 of 2020; PB 117 of 2020; PB 131 of 2020; PB 6 of 2021; PB 19 of 2021 |
Schedule 2 |
|
Schedule 2................ | am PB 112 of 2010; PB 9, 20, 27, 44, 51, 71 and 90 of 2011; PB 17, 30, 53, 81 and 99 of 2012; PB 19, 46, 68 and 76 of 2013; PB 22, 47, 54, 66, 70 and 95 2014; PB 6, 35, 75, 82, 113 and 123 of 2015; PB 7, 26, 37, 48, 70, 88 and 104 of 2016; PB 9 of 2017 (Sch 1 item 5 md not incorp); PB 22 of 2017; PB 32 of 2017; PB 41 of 2017; PB 49 of 2017; PB 60 of 2017; PB 79 of 2017; PB 97 of 2017; PB 10 of 2018; PB 25 of 2018; PB 34 of 2018; PB 43 of 2018; PB 59 of 2018; PB 70 of 2018; PB 87 of 2018; PB 104 of 2018; PB 114 of 2018; PB 5 of 2019; PB 24 of 2019; PB 41 of 2019; PB 63 of 2019; PB 81 of 2019; PB 98 of 2019; PB 8 of 2020; PB 26 of 2020; PB 48 of 2020; PB 73 of 2020; PB 95 of 2020; PB 117 of 2020; PB 6 of 2021 |